Trial Information

Summary: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of A Single-Dose Intravenous Administration Of Medi-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, On Allergen-Induced Interleukin-9 Levels In Bronchoalveolar Lavage Fluid In Adults With Atopic AsthmaProtocol MI-CP139

Do You Suffer From Asthma?


If you have allergic asthma, find out if you qualify for a clinical research study for an investigational asthma medication. You may be eligible if you:

·Have allergic asthma
·Are between the ages of 18-50

We are recruiting subjects now! Participants will be seen by a medical doctor and receive study related testing and asthma medications at no cost. It involves 12 study visits over a 6-month period and involves bronchoscopies. Compensation is up to $1650. For more information, please contact:


[Asthma Research Center, 1-888-99-ASTHMA or ARC@Partners.Org]

Contact:

Gautham Marigowda, MD, MPH
Brigham and Women's Hospital (BWH)
75 Francis Street
Boston, MA 02115
Telephone: 617-732-8201
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 3:19:18 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA